Reply  by Kloner, Robert A et al.
p
p
i
m
t
t
r
o
p
a
q
t
p
s
c
h
e
M
P
E
J
C
B
H
F
E
R
1
2
3
T
B
T
b
o
e
t
w
t
m
r
t
p
c
r
h
(
t
p
b
a
w
r
P
h
a
r
c
d
u
t
J
D
U
A
2
A
E
R
1
R
W
o
a
t
t
h
t
e
T
E
o
t
a
a
c
1
(
2
t
d
i
w
a
t
2150 Letters to the Editor JACC Vol. 43, No. 11, 2004
June 2, 2004:2147–51opulations and the heterogeneous etiology of the recurrent
ericarditis. Clearly, there is a need for an international, random-
zed study to test the effectiveness of colchicine and other treat-
ents, for example, intrapericardial triamcinolone administration
ested by Maisch et al. (3). The evaluation of the effectiveness of
reatments is difficult on the basis of single cases, as the course of
ecurrent pericarditis is unpredictable although gradually “burning
ut.” The chronicity of the condition is exemplified by two of our
atients believed to be cured of the disease, but who after the
cceptance of our article have had new relapses after 9 and 11 years’
uiescence, respectively.
Similar to Dr. Brucato and his colleagues, we find it important
o use as nontoxic drugs as possible during the acute phases of
ericarditis. However, our experience in young patients does not
upport their recommendation of routine multidrug therapy in-
luding long-term corticosteroids, colchicine, and NSAIDs. In our
ands, mere NSAID treatment was in the long run at least as
ffective as the treatment with different immunosuppressive drugs.
arja Raatikka, MD
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ime Course of the Interaction
etween Tadalafil and Nitrates
he Express Publication by Kloner et al. (1) on the interactions
etween nitrates and tadalafil should be of interest to all cardiol-
gists and physicians seeing patients with acute chest pain.
However, I have several questions: 1) What is the duration of
rectile dysfunction efficacy of tadalifil? The long half-life suggests
hat responsiveness to the drug may last 2 to 3 days; do we know
hether the blood pressure and heart rate effects of nitrates with
adalafil on board are concordant with the duration of improve-
ent in sexual function? 2) It is unclear whether there is a repeat
un-in of 7 days for both placebo and tadalafil after the cross-over,
hat is, is the second-half dosing the same as the first part of the
rotocol? 3) Why is the recommendation made to withhold
oncomitant use of a nitrate and tadalafil for 48 h when all data
obustly support no interaction at this time interval? 4) The palf-life of sildenafil, the gold standard phosphodiesterase 5
PDE5) inhibitor is not provided. This would be useful, including
he best estimate of its duration of its action, as well as the time
eriod during which there is a potentially hazardous interaction
etween this PD5 inhibitor and nitrates. 5) Is it possible that an
cute dosing interaction (no previous exposure for several days)
ith nitrates with sildenafil or tadalafil might induce a different
esponse to nitrates than after 5 to 6 consecutive half-lives of the
D5 inhibition? Thus, it may be that a form of tolerance to nitrate
emodynamic effects could develop within days in the vasculature,
ttenuating the decrease in blood pressure and increase in heart
ate after an individual has been taking a PD5 inhibitor for a
onsiderable amount of time, as in this experiment. The protocol
esign does not really mirror the way sildenafil and tadalafil are
sed in daily living. It would be useful to know if there are data
hat answer these questions.
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EPLY
e would like to thank Dr. Abrams for his questions regarding
ur study on the time course of the interaction between tadalafil
nd sublingual nitroglycerin (SL-NTG) (1). In response to ques-
ion 1 regarding the duration of efficacy: Since the publication of
he article (1), tadalafil, a phosphodiesterase 5 (PDE5) inhibitor,
as been approved by the Food and Drug Administration for the
reatment of erectile dysfunction (ED) (2). Tadalafil improves
rectile function in men with ED for up to 36 h after dosing (2,3).
herefore, the duration of efficacy of tadalafil for the treatment of
D for up to 36 h is similar to the time course of the interaction
f tadalafil with nitrates (i.e., the hemodynamic interaction be-
ween tadalafil and SL-NTG lasted 24 h but was not seen at 48 h
nd beyond).
In response to question 2 regarding study design: Our study was
randomized, placebo-controlled, double-blind, two-period,
ross-over, multicenter study (n  150). During treatment period
, subjects received seven consecutive daily doses of either tadalafil
20 mg) or placebo before SL-NTG administration. After a 10- to
1-day washout period, subjects were crossed over to the opposite
reatment (treatment period 2) and received seven consecutive
aily doses of either tadalafil or placebo before SL-NTG admin-
stration.
In response to question 3 regarding the recommendation to
ithhold nitrates for 48 h: In our study, SL-NTG (0.4 mg) was
dministered at 2, 4, 8, 24, 48, 72, and 96 h after the last dose of
adalafil 20 mg or placebo. Tadalafil augmented the blood
ressure-lowering effects of SL-NTG from 2 to 24 h post-dosing
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June 2, 2004:2147–51ompared with placebo, with no significant differences at 48, 72, or
6 h. Our study did not examine the time points between 24 and
8 h to assess when the hemodynamic interaction between tadalafil
nd SL-NTG was no longer detectable. Therefore, if deemed
edically necessary, nitrates should be administered only under
lose medical supervision with hemodynamic monitoring at 48 h
nd beyond the last dose of tadalafil.
In response to question 4 regarding the half-life of sildenafil:
he half-life of sildenafil is 4 h (4). Several studies have demon-
trated the interaction between sildenafil and organic nitrates
5–7). Recently, a preliminary study (7) performed in 33 healthy
en showed that SL-NTG, administered at multiple time points
p to 48 h post-sildenafil 100 mg or placebo dosing, produced
ecreases in mean sitting blood pressure that were significantly
ifferent (sildenafil minus placebo) only at 1 h post-sildenafil or
lacebo dosing. Although the experimental design was similar to
ur clinical trial (1), the sildenafil study only reported mean blood
ressures. Because interactions may be missed by only analyzing
ean changes in blood pressure, the number of patients with
otentially clinically significant blood pressure changes (i.e., ‘out-
iers’) should also be used to detect hemodynamic interactions
1,8,9). This preliminary sildenafil study (7) was also much smaller
han our study and was performed in healthy men only. Because of
he potential for clinically relevant hypotension, the American
ollege of Cardiology/American Heart Association Consensus
ommittee recommends that nitrates not be given until 24 h (5 to
half-lives) after taking sildenafil (4).
In response to question 5 regarding the non–steady-state dosing
f tadalafil: We examined the hemodynamic effects of SL-NTG
dministered after single doses of tadalafil (5 mg and 10 mg)
ompared with placebo (8–10). These studies examined both mean
aximal changes in blood pressure as well as blood pressure outlier
ata. Although not performed within the same study, the hemo-
ynamic interactions with nitrates after a single dose of tadalafil
ere comparable to those after steady-state dosing of tadalafil
1,8–10). Studies have not been done to examine the development
f tolerance to the hemodynamic effects of nitrates in the presence
f PDE5 inhibitors. Importantly, nitrates are contraindicated
hether a patient has been taking daily or intermittent doses of any
DE5 inhibitor (e.g., tadalafil, sildenafil, or vardenafil).obert A. Kloner, MD, PhD
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